Lipella Pharmaceuticals Inc. in brief
Lipella Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in Pittsburgh, Pennsylvania, USA. Its last known market value was $6 M (January 2024); there is no current figure. In the year to December 2024 it had sales of $1 M and a net loss of $5 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Lipella Pharmaceuticals Inc.
We are a clinical-stage biotechnology company that was incorporated under the laws of the State of Delaware in February 2005. We are focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications.
We believe that our strategy combines many of the cost efficiencies and risk abatements derived from using existing generic drugs with potential patent protections for our proprietary formulations; this strategy allows us to expedite, protect, and monetize our product candidates. Additionally, we maintain a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. We believe that this focus can potentially help reduce the cost, time and risk associated with obtaining marketing approval. We have not yet commercialized any products, and we do not expect to generate revenue from sales of any product candidates for several years.
From the company's annual report filed with the US SEC: read the report
Lipella Pharmaceuticals Inc. timeline
- 2005
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 🔔Initial public offeringFinal prospectus filed with the SEC on 21 December 2022; shares registered for exchange trading on 19 December 2022.
- 2024
- 💰Record revenue of $1 millionFY2024, the highest of the 4 years on record.
Events of Lipella Pharmaceuticals Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,220 (Dec 2022) · #5,363 (Jul 2023) · #4,604 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -929.6%
- Operating margin
- -940.7%
- Return on equity
- -261.5%
- Liabilities / assets
- 28.1%
- Revenue growth
- +20.0%
- R&D / revenue
- 668.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $1M | +20.0% | $-5M | $-5M | -929.6% |
| Dec 2023 | $0M | +150.0% | $-5M | $-5M | -1026.7% |
| Dec 2022 | $0M | -30.8% | $-3M | $-3M | -1444.4% |
| Dec 2021 | $0M | — | $-2M | $-2M | -719.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-4M | — | — | $-4.79 | — |
| Dec 2023 | $-3M | $0M | $-3M | $-6.16 | — |
| Dec 2022 | $-2M | — | — | $-0.64 | — |
| Dec 2021 | $-1M | — | — | $-0.55 | — |
Quarterly results
Latest quarter to Sep 2025: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2025.
SEC filings
- Jul 15, 20268-KCurrent reportBankruptcy
- Mar 31, 20268-KCurrent reportBankruptcy
- Feb 4, 20268-KCurrent reportDirectors or officers changed
- Nov 14, 202510-QQuarterly report · period to Sep 2025
- Oct 21, 20258-KCurrent reportDirectors or officers changed
- Oct 9, 20258-KCurrent reportDirectors or officers changed
- Sep 18, 20258-KCurrent reportRegulation FD disclosure · Other events
- Aug 14, 202510-QQuarterly report · period to Jun 2025
- Jun 25, 20258-KCurrent reportRegulation FD disclosure · Other events
- Jun 20, 20258-KCurrent reportListing notice · Regulation FD disclosure
- Jun 16, 20258-KCurrent reportOther events
- May 16, 20258-KCurrent reportListing notice
Official filings of Lipella Pharmaceuticals Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-5 M
- Net income
- $-5 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $3 M
- Total liabilities
- $1 M
- Total equity
- $2 M
As of December-2024
Insider trading at Lipella Pharmaceuticals Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jonathan H. KaufmanSee remarks below., Director, 10% owner | Buy | +10,000 | $0.760 | $8 K | 898,849 | Form 4 |
| filed | Jonathan H. KaufmanSee remarks below., Director, 10% owner | Buy | +25,000 | $0.870 | $22 K | 888,849 | Form 4 |
| filed | Jonathan H. KaufmanSee remarks below., Director, 10% owner | Buy | +30,000 | $0.790 | $24 K | 863,849 | Form 4 |
| filed | Jonathan H. KaufmanSee remarks below., Director, 10% owner | Grant or award | +144,906 | $0.690 | $100 K | 833,849 | Form 4 |
| filed | Michael B. ChancellorChief Medical Officer, Director, 10% owner | Grant or award | +144,906 | $0.690 | $100 K | 877,637 | Form 4 |
| filed | Michael B. ChancellorChief Medical Officer, Director, 10% owner | Other | +22,950 | $5.750 | $132 K | 732,730 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Lipella Pharmaceuticals Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lipella Pharmaceuticals Inc. scorecard#
Passes 1 of the 6 checks that could be worked out. Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.79 vs -6.16Diluted EPS -4.79 in fiscal 2024 against -6.16 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2024.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-198.4%-198.4% in fiscal 2024.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.49 at the end of fiscal 2024.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year39.7%Diluted shares up 39.7% in fiscal 2024.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Lipella Pharmaceuticals Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 536+19.3%100% | 450+144%100% | 184−29.0%100% | 259—100% | |
| Research and development | 3,613+18.9%674% | 3,039+19.3%676% | 2,548+74.9%1383% | 1,457—562% | |
| General and administrative | 2,004−7.1%374% | 2,157+853%480% | 226−68.5%123% | 718—277% | |
| Operating income | −5,081—−947% | −4,746—−1056% | −2,590—−1406% | −1,916—−739% | |
| Interest and finance income | 64−53.4%12.0% | 138+8114%30.7% | 1.7+1513%0.9% | 0.1—0.0% | |
| Interest expense and finance costs | — | 11+12.9%2.4% | 9.6+40.6%5.2% | 6.8—2.6% | |
| Other non-operating income (expense) | 64−49.4%12.0% | 127—28.2% | −8.0−116%−4.3% | 50—19.4% | |
| Income before tax | −5,016—−935% | −4,619—−1027% | −2,598—−1411% | −1,865—−719% | |
| Net income attributable to shareholders | −5,016—−935% | −4,619—−1027% | −2,598—−1411% | −1,865—−719% | |
| Earnings per share, basic | -4.79—— | -6.16r-0.77—— | -0.64—— | -0.55—— | |
| Earnings per share, diluted | -4.79—— | -6.16r-0.77—— | -0.64—— | -0.55—— | |
| Shares, weighted average (basic) | 1.0+39.7%— | 0.8r6.0−81.5%— | 4.1+19.1%— | 3.4—— | |
| Shares, weighted average (diluted) | 1.0+39.7%— | 0.8r6.0−81.5%— | 4.1+19.1%— | 3.4—— | |
| Balance sheet | |||||
| Cash and cash equivalents | 2,185−33.7%81.7% | 3,294−35.7%92.1% | 5,122+262%86.1% | 1,414—70.2% | |
| Short-term investments | — | — | — | 301—14.9% | |
| Receivables | 85+162%3.2% | 32−71.6%0.9% | 114—1.9% | — | |
| Current assets | 2,617−23.7%97.9% | 3,429−40.9%95.9% | 5,799+221%97.5% | 1,808—89.8% | |
| Property, plant and equipment | 9.9−22.6%0.4% | 13—0.4% | — | — | |
| Right-of-use (leased) assets | 47−65.4%1.7% | 135−10.4%3.8% | 151−26.4%2.5% | 205—10.2% | |
| Total assets | 2,674−25.3%100% | 3,577−39.9%100% | 5,950+196%100% | 2,013—100% | |
| Accounts payable | 388+181%14.5% | 138−64.1%3.9% | 384+720%6.5% | 47—2.3% | |
| Current liabilities | 754+95.8%28.2% | 385−67.3%10.8% | 1,178+246%19.8% | 341—16.9% | |
| Lease liabilities (non-current) | — | 47−50.8%1.3% | 96−42.8%1.6% | 168—8.4% | |
| Total liabilities | 754+74.3%28.2% | 433−66.0%12.1% | 1,275+116%21.4% | 589—29.3% | |
| Retained earnings | −15,340—−574% | −10,324—−289% | −5,705—−95.9% | −3,107—−154% | |
| Shareholders' equity | 1,919−39.0%71.8% | 3,144−32.7%87.9% | 4,676+228%78.6% | 1,424—70.7% | |
| Total liabilities and equity | 2,674−25.3%100% | 3,577−39.9%100% | 5,950+196%100% | 2,013—100% | |
| Shares outstanding | 1.2+59.8%— | 0.8r6.1−86.8%— | 5.7r5.7+48.6%— | 3.9—— | |
| Cash-flow statement | |||||
| Depreciation and amortization | 2.9+71.3%0.5% | 1.7—0.4% | — | — | |
| Cash from operating activities | −3,951—−737% | −3,150—−701% | −1,831—−994% | −989—−381% | |
| Capital expenditure | — | −14—−3.2% | — | — | |
| Cash from investing activities | — | −14−105%−3.2% | 301—163% | −301—−116% | |
| Shares issued | — | — | 4,964+137%2695% | 2,097—809% | |
| Cash from financing activities | 2,842+113%530% | 1,337−74.5%297% | 5,239+150%2845% | 2,097—809% | |
| Report | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | 390−19.4%100% | 0*−100%— | 87−36.4%100% | 129−11.3%100% | 174*+43.7%100% | 80−22.7%100% | 136+27.9%100% | 146+23.6%100% | 121*—100% | 104—100% | 107—100% | 118—100% | |
| Research and development | 3,568+18.7%915% | 721−31.1%— | 792+19.7%913% | 993+17.9%768% | 1,062*+134%612% | 1,047+25.6%1302% | 662−37.4%485% | 843+21.5%578% | 454*—376% | 833—801% | 1,058—991% | 694—588% | |
| General and administrative | 2,231+21.4%572% | 553+12.2%— | 652+52.6%751% | 464−11.0%358% | 563*+42.0%324% | 493−21.4%613% | 427−31.6%313% | 521+2.4%357% | 396*—328% | 628—603% | 624—585% | 509—431% | |
| Operating income | −5,410—−1388% | −1,274—— | −1,357—−1564% | −1,328—−1026% | −1,451*—−836% | −1,459—−1816% | −952—−698% | −1,218—−835% | −730*—−604% | −1,357—−1304% | −1,575—−1477% | −1,084—−919% | |
| Interest and finance income | 80−15.9%20.6% | 20+36.6%— | 29+107%33.5% | 21−17.6%16.5% | 9.6*−76.4%5.5% | 15−55.4%18.4% | 14−66.5%10.3% | 26+17.4%17.7% | 41*—33.7% | 33—31.9% | 42—39.3% | 22—18.6% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 5.5—5.1% | 5.4—4.6% | |
| Other non-operating income (expense) | 80−15.9%20.6% | 20+36.6%— | 29+107%33.5% | 21−17.6%16.5% | 9.6*−76.4%5.5% | 15−55.4%18.4% | 14−61.5%10.3% | 26+55.6%17.7% | 41*—33.7% | 33—31.9% | 37—34.2% | 17—14.1% | |
| Income before tax | −5,330—−1367% | −1,254—— | −1,327—−1531% | −1,307—−1010% | −1,442*—−830% | −1,445—−1797% | −938—−688% | −1,192—−817% | −689*—−570% | −1,324—−1272% | −1,539—−1442% | −1,068—−905% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | −1,324*—−1272% | — | — | |
| Net income attributable to shareholders | −5,330—−1367% | −1,254—— | −1,327—−1531% | −1,307—−1010% | −1,442*—−830% | −1,445—−1797% | −938—−688% | −1,192—−817% | −689*—−570% | −1,324—−1272% | −1,539—−1442% | −1,068—−905% | |
| Earnings per share, basic | — | -0.28—— | -0.31—— | -0.64—— | — | -1.29—— | -0.99r-0.12—— | -1.31r-0.16—— | — | -1.84r-0.23—— | -0.27—— | -0.19—— | |
| Earnings per share, diluted | — | -0.28—— | -0.31—— | -0.64—— | — | -1.29—— | -0.99r-0.12—— | -1.31r-0.16—— | — | -1.84r-0.23—— | -0.27—— | -0.19—— | |
| Shares, weighted average (basic) | 4.5+306%— | 4.5+306%— | 4.3+353%— | 2.1+126%— | — | 1.1+55.6%— | 1.0r7.6−83.4%— | 0.9r7.3−84.1%— | — | 0.7r5.8—— | 5.7—— | 5.7—— | |
| Shares, weighted average (diluted) | 4.5+306%— | 4.5+306%— | 4.3+353%— | 2.1+126%— | — | 1.1+55.6%— | 1.0r7.6−83.4%— | 0.9r7.3−84.1%— | — | 0.7r5.8—— | 5.7—— | 5.7—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 1,856—79.0% | 1,856+37.1%79.0% | 2,782+134%74.8% | 4,225+101%87.0% | 2,185−33.7%81.7% | 1,354−43.8%62.7% | 1,187−61.9%54.3% | 2,105−47.6%67.1% | 3,294—92.1% | 2,410—84.8% | 3,114—89.2% | 4,019—87.1% | |
| Receivables | — | — | — | — | 85+162%3.2% | 31−41.5%1.4% | 35+26.0%1.6% | 69−17.9%2.2% | 32—0.9% | 53—1.9% | 28—0.8% | 84—1.8% | |
| Current assets | 2,079—88.5% | 2,079−0.0%88.5% | 3,437+65.2%92.4% | 4,823+60.2%99.3% | 2,617−23.7%97.9% | 2,080−22.1%96.3% | 2,081−38.2%95.3% | 3,011−32.8%96.0% | 3,429—95.9% | 2,671—94.0% | 3,367—96.5% | 4,478—97.0% | |
| Property, plant and equipment | 7.7—0.3% | 7.7−27.3%0.3% | 8.4−25.5%0.2% | 9.1−24.0%0.2% | 9.9−22.6%0.4% | 11−21.4%0.5% | 11—0.5% | 12—0.4% | 13—0.4% | 13—0.5% | — | — | |
| Right-of-use (leased) assets | 263—11.2% | 263+278%11.2% | 275+198%7.4% | 24−79.3%0.5% | 47−65.4%1.7% | 70−55.5%3.2% | 92−24.9%4.2% | 114−16.6%3.6% | 135—3.8% | 156—5.5% | 123—3.5% | 137—3.0% | |
| Total assets | 2,350—100% | 2,350+8.8%100% | 3,720+70.3%100% | 4,856+54.8%100% | 2,674−25.3%100% | 2,160−24.0%100% | 2,184−37.4%100% | 3,137−32.0%100% | 3,577—100% | 2,841—100% | 3,490—100% | 4,615—100% | |
| Accounts payable | 463—19.7% | 463+0.7%19.7% | 608+241%16.3% | 392+33.4%8.1% | 388+181%14.5% | 459+51.6%21.3% | 178+709%8.2% | 294+97.3%9.4% | 138—3.9% | 303—10.7% | 22—0.6% | 149—3.2% | |
| Current liabilities | 642—27.3% | 642−8.4%27.3% | 747+55.5%20.1% | 777+40.8%16.0% | 754+95.8%28.2% | 701+27.8%32.5% | 480+60.7%22.0% | 552−23.1%17.6% | 385—10.8% | 549—19.3% | 299—8.6% | 717—15.5% | |
| Lease liabilities (non-current) | 220—9.4% | 220—9.4% | 232—6.2% | — | — | — | — | 24−70.4%0.8% | 47—1.3% | 70—2.5% | 65—1.9% | 81—1.8% | |
| Total liabilities | 862—36.7% | 862+23.0%36.7% | 979+104%26.3% | 777+34.9%16.0% | 754+74.3%28.2% | 701+13.2%32.5% | 480+31.9%22.0% | 576−27.9%18.4% | 433—12.1% | 619—21.8% | 364—10.4% | 798—17.3% | |
| Retained earnings | −19,228—−818% | −19,228—−818% | −17,974—−483% | −16,647—−343% | −15,340—−574% | −13,898—−643% | −12,454—−570% | −11,516—−367% | −10,324—−289% | −9,635—−339% | −8,311—−238% | −6,773—−147% | |
| Shareholders' equity | 1,488—63.3% | 1,488+2.0%63.3% | 2,742+60.9%73.7% | 4,079+59.3%84.0% | 1,919−39.0%71.8% | 1,459−34.3%67.5% | 1,704−45.5%78.0% | 2,561r2,561−32.9%81.6% | 3,144—87.9% | 2,222—78.2% | 3,125—89.6% | 3,816—82.7% | |
| Total liabilities and equity | 2,350—100% | 2,350+8.8%100% | 3,720+70.3%100% | 4,856+54.8%100% | 2,674−25.3%100% | 2,160−24.0%100% | 2,184−37.4%100.0% | 3,137−32.0%100% | 3,577—100% | 2,841—100% | 3,490—100% | 4,615—100% | |
| Shares outstanding | 4.6—— | 4.6+323%— | 4.5−41.3%— | 2.5−63.8%— | 1.2+59.8%— | 1.1−81.2%— | 7.6+32.4%— | 7.0+22.6%— | 0.8r6.1—— | 5.8—— | 5.7—— | 5.7—— | |
| Cash-flow statement | |||||||||||||
| Depreciation and amortization | 2.9−0.1%0.7% | 0.7*0.0%— | 0.7*−0.1%0.8% | 0.7+0.1%0.6% | 0.7*−0.3%0.4% | 0.7*—0.9% | 0.7r1.4*—0.5% | 0.7r0.1—0.5% | 0.7*—0.6% | — | — | — | |
| Cash from operating activities | −4,776—−1225% | −926*—— | −1,433*—−1652% | −1,426—−1102% | −990*—−570% | −653*—−813% | −919r−919*—−673% | −1,388r−1,388—−952% | −728*—−602% | −689*—−663% | −655*—−614% | −1,078—−913% | |
| Capital expenditure | — | — | — | — | — | — | — | — | 0*—0.0% | — | — | — | |
| Cash from investing activities | — | — | — | — | — | — | — | — | 0*—0.0% | — | — | — | |
| Shares issued | — | 0*−100%— | −10*—−11.6% | 3,466+1633%2679% | — | 820*—1021% | 0*—0.0% | 200—137% | — | — | — | — | |
| Cash from financing activities | 5,278+101%1354% | 0*−100%— | −10*—−11.6% | 3,466+1633%2679% | 1,822*+13.0%1049% | 820*—1021% | 0*—0.0% | 200—137% | 1,612*—1334% | 0*—0.0% | −250*—−234% | −25—−21.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Lipella Pharmaceuticals Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Bankruptcy or receivershipFiling
- Bankruptcy or receivershipFiling
- Delisting noticeFiling
- Delisting noticeFiling
- Delisting noticeFiling
- Delisting noticeFiling
And 1 more in the list below.
Bankruptcy or receivership 2 · Delisting notice 5 · Directors and officers 3 · Material agreement 8 · Unregistered share sale 6 · Shareholder rights changed 3 · Bylaws or fiscal year changed 3 · Shareholder vote 1
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivership | 8-K | |
| Bankruptcy or receivership | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jul 15, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Lipella Pharmaceuticals Inc. compares in Biotechnology
- Revenue$1 M · higher than 21% of 647
- Net margin-929.6% · higher than 1% of 408
- Revenue growth20.0% · higher than 61% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Lipella Pharmaceuticals Inc.🇺🇸 | $6 M | — | -929.6% | +20.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Lipella Pharmaceuticals Inc.? Verify and update this profile — free
Show Lipella Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.